eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2017
vol. 42
 
Share:
Send email
Share:
abstract:
Review paper

Myeloid-derived suppressor cells in ovarian cancer: friend or foe?

Monika Walankiewicz
,
Ewelina Grywalska
,
Grzegorz Polak
,
Jan Kotarski
,
Dorota J. Siwicka-Gieroba
,
Jacek Roliński

(Centr Eur J Immunol 2017; 42 (4): 383-389)
DOI: https://doi.org/10.5114/ceji.2017.72823
Online publish date: 2017/12/30
View full text Get citation
 
PlumX metrics:
Although previous decades contributed to major progress in targeted therapy of many malignancies, the treatment of gynaecological cancers remains a challenging task. In the evidence of rising cancer mortality, the search for new methods of treatment is a dire need. Exploring the mechanisms of interaction between tumour cells and host immune response may allow the introduction of new, effective therapies – not as toxic and far more efficient than conventional methods of cancer treatment. Epithelial ovarian cancer (EOC) is typically diagnosed at advanced stages. Its incidence and mortality rate is high. Powerful diagnostic tools for this kind of cancer are still under investigation. Multiple mechanisms existing in the ovarian tumour network create a specific immunosuppressive microenvironment, in which accumulation of myeloid-derived suppressor cells (MDSCs) may be a critical component for diagnosis and treatment. This review attempts to verify current knowledge on the role of MDSCs in EOC.
keywords:

ovarian cancer, myeloid-derived suppressor cells (MDSCs), T cells

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.